# PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Canonical URL: https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-announces-promising-rezatapopt-monotherapy-interim-data-from-pynnacle-phase-2-trial-across-multiple-solid-tumors-with-a-tp53-y220c-mutation
Ticker: PMVP
Company: PMV Pharmaceuticals
Source: PMV Pharmaceuticals
Published: 2025-09-10 11:00 EST
Original Source URL: https://ir.pmvpharma.com
## Summary

PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma 33% overall response rate (ORR) observed among 97 evaluable patients across all

## Article Body
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma 33% overall response rate (ORR) observed among 97 evaluable patients across all
## Recent Company News
- 2026-05-12 12:00 EST — [PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-first-quarter-2026-financial-results-and-corporate-highlights) — Source: PMV Pharmaceuticals
- 2026-04-22 12:00 EST — [PMV Pharmaceuticals Announces Board Chair Transition](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-announces-board-chair-transition) — Source: PMV Pharmaceuticals
- 2026-03-06 13:00 EST — [PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and-corporate-highlights) — Source: PMV Pharmaceuticals
- 2026-02-26 13:00 EST — [New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors](https://biopharmsignal.com/news/PMVP/new-england-journal-of-medicine-publishes-first-in-human-rezatapopt-data-showing-selective-reactivation-of-mutant-p53-in-advanced-solid-tumors) — Source: PMV Pharmaceuticals
- 2025-11-12 13:01 EST — [PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-third-quarter-2025-financial-results-and-corporate-highlights) — Source: PMV Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)